Illumina, Inc.
A maker of DNA sequencing and genetic analysis instruments, Illumina is one of the world's largest genomics technology companies, serving researchers and clinicians in noninvasive prenatal testing and cancer detection. Founded in 1998 in San Diego by a venture capitalist and a Tufts chemist, its name comes from the Latin word for 'light,' a nod to its fluorescence-based detection—and despite how it sounds, it has nothing to do with the Illuminati. Sequencing machines like the MiSeq decode genomes.
10-Q · Quarter ended Jun 28, 2026 · SEC filing ↗
The annual decline that started in Q2 FY2023 has ended. Revenue rose 9.4% to $1,159.0M in Q2 FY2026, was 66.4%, and climbed 14.5% to $245.0M as the underlying business held profitable for a seventh straight quarter. The company has returned to growth with intact.
Market-risk exposures were unchanged in YTD 2026 versus the FY2025 10-K, with no new sensitivity figures disclosed.